![Chun Yu Pan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chun Yu Pan
Direktor/Vorstandsmitglied bei UWELL Biopharma, Inc.
Aktive Positionen von Chun Yu Pan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Chun Yu Pan
Ehemalige bekannte Positionen von Chun Yu Pan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VECTORITE BIOMEDICAL INC. | Direktor/Vorstandsmitglied | 03.06.2011 | - |
Public Communications Contact | - | - | |
Corporate Officer/Principal | 05.09.2014 | - | |
SHANGYA TECHNOLOGY CO., LTD. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Chun Yu Pan
Chinese Culture University | Masters Business Admin |
Statistik
International
Taiwan | 5 |
Operativ
Director/Board Member | 3 |
Masters Business Admin | 1 |
Public Communications Contact | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Transportation | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
SHANGYA TECHNOLOGY CO., LTD. | Health Technology |
VECTORITE BIOMEDICAL INC. | Transportation |
Private Unternehmen | 1 |
---|---|
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Health Technology |
- Börse
- Insiders
- Chun Yu Pan
- Erfahrung